Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Director's dealing

12 Dec 2011 07:00

RNS Number : 7353T
Synairgen plc
12 December 2011
 



12 December 2011

Synairgen plc

("Synairgen" or the "Company")

 

Director's dealing

 

Synairgen plc (AIM: SNG) has received notification that, on 9 December 2011, Mr Paul Clegg, a non-executive director of the Company, transferred 80,000 shares of his shareholding in the Company into his pension plan, held in the name of Wertheim Securities Paul Clegg.

 

Following this transfer of shares in Synairgen, Mr Clegg's beneficial holding remains unchanged at 184,095 ordinary shares, which represents 0.26% of the Company's issued share capital.

 

 

For further information:

 

Synairgen Plc

Richard Marsden, CEO

John Ward, Finance Director

 

+44 (0)23 8051 2800

 

finnCap Ltd

Geoff Nash

Christopher Raggett

 

 

+44 (0)20 7220 0500

 

Threadneedle Communications

Graham Herring

Josh Royston

 

+44 (0)20 7653 9850

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUKRBRAKAURAA
Date   Source Headline
21st Sep 20217:00 amRNSSynairgen Notice of Interim Results
10th Sep 202111:30 amRNSHolding(s) in Company
12th Aug 20214:12 pmRNSExercise of Options and Total Voting Rights
6th Aug 202112:21 pmRNSHolding(s) in Company
29th Jun 20214:28 pmRNSHolding(s) in Company
18th Jun 202110:29 amRNSResult of AGM
7th Jun 20217:00 amRNSGrant of Options
25th May 20214:28 pmRNSNotice of AGM
24th May 20217:00 amRNSResults of in vitro studies
12th May 20217:00 amRNSFull Year Results
30th Apr 20217:00 amRNSHome Cohort data of SG016 Phase II trial
16th Apr 20214:37 pmRNSHolding(s) in Company
15th Apr 202111:44 amRNSHolding(s) in Company
6th Apr 20214:36 pmRNSHolding(s) in Company
15th Feb 20217:00 amRNSDosing commenced in US ACTIV-2 trial
25th Jan 20217:00 amRNSInclusion in US ACTIV-2 trial
20th Jan 20217:00 amRNSHome trial recruitment completed
13th Jan 20217:00 amRNSFirst Patient Dosing in Phase III SG018 Trial
6th Jan 20215:10 pmRNSHolding(s) in Company
5th Jan 20215:53 pmRNSHolding(s) in Company
18th Dec 20207:00 amRNSCOVID-19 Clinical Programme Update
10th Dec 202012:57 pmRNSHolding(s) in Company
13th Nov 20205:03 pmRNSHolding(s) in Company
13th Nov 20207:00 amRNSLancet Respiratory Medicine publishes Phase 2 data
10th Nov 20201:47 pmRNSHolding(s) in Company
4th Nov 20205:51 pmRNSHolding(s) in Company
3rd Nov 20209:00 amRNSHolding(s) in Company
2nd Nov 202012:20 pmRNSResult of General Meeting and Total Voting Rights
2nd Nov 20207:00 amRNSResult of Open Offer
28th Oct 202011:20 amRNSHolding(s) in Company
27th Oct 20208:35 amRNSHolding(s) in Company
21st Oct 20209:45 amRNSHolding(s) in Company
21st Oct 20209:40 amRNSHolding(s) in Company
16th Oct 20203:10 pmRNSExercise of Options and Total Voting Rights
15th Oct 20205:35 pmRNSExercise of Options and Total Voting Rights
15th Oct 20201:51 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSResults of Placing
14th Oct 20205:32 pmRNSPlacing and Open Offer
12th Oct 202011:05 amRNSSecond Price Monitoring Extn
12th Oct 202011:00 amRNSPrice Monitoring Extension
6th Oct 20208:55 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSAppointment of Joint Broker
1st Oct 20202:06 pmRNSSecond Price Monitoring Extn
1st Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 202011:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSClinigen signs MAP agreement with Synairgen
29th Sep 20207:00 amRNSSynairgen and Clinigen sign Managed Access Program
29th Sep 20207:00 amRNSInterim results for six months ended 30 June 2020
9th Sep 20207:00 amRNSSynairgen IP Update
8th Sep 20207:00 amRNSPositive interim analysis of SNG001 in COPD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.